Evidence map›Paper›PMID 27624749›Full record

ArticleBMC nephrology2016

Serum cystatin is a useful marker for the diagnosis of acute kidney injury in critically ill children: prospective cohort study.

Osama Y Safdar, Mohammed Shalaby, Norah Khathlan, Bassem Elattal, Mohammed Bin Joubah, Esraa Bukahri, Mafaza Saber, Arwa Alahadal, Hala Aljariry, Safaa Gasim and 4 more

Open access · goldAbstract read
In one paragraph

Article in BMC nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Osama Y SafdarPediatric Nephrology Unit, Department of Pediatrics, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia. safderosama@hotmail.com.
Mohammed ShalabyPediatric Nephrology Unit, Department of Pediatrics, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Norah KhathlanIntensive Care Unit, Department of Pediatrics, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Bassem ElattalDepartment of Pediatrics, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Mohammed Bin JoubahDepartment of Pediatrics, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Esraa BukahriDepartment of Pediatrics, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Mafaza SaberDepartment of Pediatrics, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Arwa AlahadalDepartment of Pediatrics, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Hala AljariryDepartment of Pediatrics, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Safaa GasimDepartment of Pediatrics, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Afnan HadadiFaculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Abdullah AlqahtaniKing Abdullah Specialized Children Hospital, King Abdulaziz Medical City, Riyadh, Kingdom of Saudi Arabia.
Roaa AwleyakhanDepartment of Pediatrics, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Jameela A KariPediatric Nephrology Unit, Department of Pediatrics, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
King Abdulaziz University · SAKing Abdulaziz Medical City · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute kidney injury (AKI) has been associated with high morbidity and mortality rates among critically ill children. Cystatin C is a protease inhibitor, and studies have shown that it is a promising marker for the early diagnosis of AKI. Our goal in this study was to assess whether serum cystatin C could serve as an accurate marker for the diagnosis of AKI.

methodsThis prospective study was undertaken in the pediatric intensive care unit at King Abdulaziz University Hospital. Serum creatinine and serum cystatin C levels were both measured in patients on admission (0 h) and at 6, 12, and 24 h after admission. AKI was diagnosed according to the modified pRIFLE criteria. Receiver operating characteristic (ROC) curve analysis was performed to assess the utility of serum cystatin C for diagnosing AKI.

resultsA total of 62 patients were enrolled in this study, and 32 were diagnosed with AKI according to the modified pRIFLE criteria (51.4 %). The area under the ROC curve for serum cystatin indicated that it was a good marker for the diagnosis of AKI at 0, 6, 12 and 24 h, with sensitivities of 78, 94, 94 and 83 %, respectively. However, the specificities of serum cystatin C at 0, 6, 12, and 24 h were 57, 57, 60 and 50 %, respectively. The optimal cutoff value was 0.645 mg/L. The area under the ROC for serum creatinine showed sensitivities of 50, 65.4, 69.2 and 57.7 % and specificities of 67.7, 70, 60 and 70 % at 0, 6, 12 and 24 h, respectively. The optimal cutoff value for serum creatinine was 30 μmol/l. Comparisons of ROC curves revealed that serum cystatin C was superior to serum creatinine for the diagnosis of AKI at 12 h (p = 0.03), but no differences were detected at 0, 6 or 24 h.

conclusionSerum cystatin is a sensitive, but not a specific, marker for the diagnosis of AKI in critically ill children.

Indexed as

Acute Kidney InjuryArea Under CurveBiomarkersChild, PreschoolCreatinineCritical IllnessCystatin CFemaleHumansInfantMaleProspective StudiesROC CurveTime FactorsBiomarkersCreatinineCystatin CAcute kidney injuryCreatinineCystatin CPediatric

Identifiers

PMID27624749
PMCPMC5022154
OpenAlexW2519292205

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.